Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.

The trial laid the foundation for the Comparative Immunotherapy Program — a program launched a year ago to tap into Penn’s ...

Researchers at the ESMO Congress said they want to confirm their findings in a prospective randomized controlled trial.

At Ochsner Cancer Center of Acadiana, people diagnosed with blood cancers find more than the latest treatments — they also ...

FDA fast-tracks EO2463 immunotherapy for follicular lymphoma, promising a new treatment option backed by positive trial data ...

Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, ...

A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the ...

The FDA has approved the combination of lurbinectedin (Zepzelca) and the immunotherapy atezolizumab (Tecentriq) for first-line maintenance treatment in patients with extensive-stage small cell lung ...

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...